1. Home
  2. NUS vs IMMP Comparison

NUS vs IMMP Comparison

Compare NUS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$10.64

Market Cap

603.4M

Sector

Health Care

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.56

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUS
IMMP
Founded
1984
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
603.4M
264.9M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NUS
IMMP
Price
$10.64
$2.56
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
404.5K
1.7M
Earning Date
11-06-2025
02-22-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
N/A
EPS
2.20
N/A
Revenue
$1,560,391,000.00
$3,306,742.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.12
N/A
P/E Ratio
$4.81
N/A
Revenue Growth
N/A
31.28
52 Week Low
$5.32
$1.32
52 Week High
$14.62
$3.53

Technical Indicators

Market Signals
Indicator
NUS
IMMP
Relative Strength Index (RSI) 58.56 72.34
Support Level $9.63 $1.67
Resistance Level $10.18 $2.68
Average True Range (ATR) 0.31 0.25
MACD 0.12 0.09
Stochastic Oscillator 92.66 48.12

Price Performance

Historical Comparison
NUS
IMMP

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: